Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.

The Journal of clinical investigation - 3 Nov 2025

Esmaeili Shadisadat, Owens Katherine, de Leon Ugo Avila-Ponce, Standing Joseph F, Lowe David M, Zhang Shengyuan, Watson James A, Schilling William Hk, Wagoner Jessica, Polyak Stephen J, Schiffer Joshua T

Abstract excerpt

Molnupiravir is an antiviral medicine that induces lethal copying errors during SARS-CoV-2 RNA replication. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials. We used mathematical models to simulate these trials and closely recapitulated their virologic outcomes. Model simulations suggested lower antiviral potency...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Cytidine

Share to Hydroxylamines

Share to Ribonucleotides

Share to SARS-CoV-2

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 40934429
DOI: 10.1172/JCI192052
PMCID: PMC12578382

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.PMID 40934429Read ↗

Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2Semantic proximity Read ↗

The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19Semantic proximity Read ↗

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobodySemantic proximity Read ↗

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read ↗

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness.Semantic proximity Read ↗

A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe.Semantic proximity Read ↗

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.Semantic proximity Read ↗

SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participantsSemantic proximity Read ↗

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.Semantic proximity Read ↗

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesisSemantic proximity Read ↗

Plasma concentrations of nirmatrelvir and molnupiravir required for inhibition of SARS-CoV-2 replication differ between rhesus macaques and humansSemantic proximity Read ↗

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.